Variation in drug response related to polymorphisms in .beta.2-adrenergic receptor
Number of patents in Portfolio can not be more than 2000
United States of America Patent
Stats
-
Sep 28, 2004
Grant Date -
N/A
app pub date -
Dec 17, 2001
filing date -
Mar 12, 1999
priority date (Note) -
Expired
status (Latency Note)
Importance
Abstract
A method for predicting an individual's response to the .beta.-agonists salmeterol, albuterol, metaproterenol, terbutaline and formoterol is disclosed. Individuals expressing the Ile164 .beta..sub.2 AR variant are likely to exhibit a reduced response as compared to individuals expressing the Thr164 .beta..sub.2 AR variant. The method is useful for making treatment decisions for patients suffering from asthma and chronic obstructive pulmonary diseases.
First Claim
Family
International Classification(s)
- [Classification Symbol]
- [Patents Count]
Cited Art Landscape
Patent Citation Ranking
Advertisement
Advertisement
Advertisement
Recipient Email Address
Recipient Email Address
Comment
Recipient Email Address
Add to Portfolio(s)
To add this patent to one, or more, of your portfolios, simply click the add button.
This Patent is in these Portfolios:
Add to additional portfolios:
Last Refreshed On:
Changes done successfully